CM
SCPH

Caption Management’s scPharmaceuticals SCPH Stock Holding History

Caption Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$251K – 1466
2024
Q1 		$251K Hold
50,000
– – ﹤0.01% 975
2023
Q4 		$314K Buy
+50,000
New +$286K ﹤0.01% 1049

Other funds holding SCPH

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caption Management's SCPH Position: Q2 2024 in Review

Caption Management sold out of scPharmaceuticals (SCPH) in Q2 2024, closing a stake of 7,667 shares — an estimated $38.5K sold.

Caption Management first reported a position in SCPH in Q4 2023 and held it in 2 quarters. The position peaked at $48.1K in Q4 2023. 77 funds tracked by Wall St. Rank hold SCPH as of Q2 2024.

  • Caption Management reported no remaining scPharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Caption Management sold 7,667 scPharmaceuticals shares in Q2 2024, an estimated $38.5K.
  • Caption Management first reported a position in scPharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Caption Management's scPharmaceuticals position peaked at $48.1K in Q4 2023.
  • 77 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2024.

Based on Caption Management's 13F filing for Q2 2024, filed 14 Aug 2024.